Cui AL - Search Results

1

Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria.

Cui AL, Yang HX, Yi H, Lv M, Peng XJ, Zheng GH, Li ZR. Cui AL, et al. Eur J Med Chem. 2024 Sep 28;280:116924. doi: 10.1016/j.ejmech.2024.116924. Online ahead of print. Eur J Med Chem. 2024. PMID: 39383655

2

Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics.

Cui AL, Hu XX, Gao Y, Jin J, Yi H, Wang XK, Nie TY, Chen Y, He QY, Guo HF, Jiang JD, You XF, Li ZR. Cui AL, et al. J Med Chem. 2018 Mar 8;61(5):1845-1857. doi: 10.1021/acs.jmedchem.7b01367. Epub 2018 Feb 15. J Med Chem. 2018. PMID: 29412662

3

Design, synthesis, and antibacterial activity of derivatives of Tryptophanyl-tRNA synthetase inhibitor indolmycin.

Sun L, Zhang S, Kou S, Yi H, Cui A, Li Z. Sun L, et al. Eur J Med Chem. 2022 Nov 5;241:114647. doi: 10.1016/j.ejmech.2022.114647. Epub 2022 Aug 8. Eur J Med Chem. 2022. PMID: 35963132

4

Design, Synthesis, and Bioactivity Investigation of Cyclic Lipopeptide Antibiotics Containing Eight to Nine Amino Acids.

Yang HX, Xie ZS, Yi H, Jin J, Geng J, Cui AL, Li ZR. Yang HX, et al. Among authors: cui al. J Med Chem. 2023 Feb 23;66(4):2524-2541. doi: 10.1021/acs.jmedchem.2c01344. Epub 2023 Feb 5. J Med Chem. 2023. PMID: 36739537

5

Design, Synthesis, and Bioactivity of Cyclic Lipopeptide Antibiotics with Varied Polarity, Hydrophobicity, and Positive Charge Distribution.

Cui AL, Hu XX, Chen Y, Jin J, Yi H, Wang XK, He QY, You XF, Li ZR. Cui AL, et al. ACS Infect Dis. 2020 Jul 10;6(7):1796-1806. doi: 10.1021/acsinfecdis.0c00056. Epub 2020 May 6. ACS Infect Dis. 2020. PMID: 32330004

6

Synthesis and anti-ovarian cancer effects of benzimidazole-2-substituted pyridine and phenyl propenone derivatives.

Cui AL, Zhou ZY, Wang YL, Wu LT, Xue ST, Li ZR. Cui AL, et al. Future Med Chem. 2022 Dec;14(24):1835-1846. doi: 10.4155/fmc-2022-0244. Epub 2022 Nov 14. Future Med Chem. 2022. PMID: 36373543

7

Polymyxin-based fluorescent probes to combat Gram-negative antimicrobial resistance.

Han X, Cui AL, Yang HX, Wu L, Wei R, Liu Q, Li ZR, Hu HY. Han X, et al. Among authors: cui al. Talanta. 2023 Aug 1;260:124576. doi: 10.1016/j.talanta.2023.124576. Epub 2023 Apr 25. Talanta. 2023. PMID: 37148689

8

hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.

Sun LP, Bai WQ, Zhou DD, Wu XF, Zhang LW, Cui AL, Xie ZH, Gao RJ, Zhen YS, Li ZR, Miao QF. Sun LP, et al. Among authors: cui al. J Med Chem. 2023 Nov 9;66(21):14700-14715. doi: 10.1021/acs.jmedchem.3c01210. Epub 2023 Oct 26. J Med Chem. 2023. PMID: 37883180

9

Synthesis and Bioactivity of N-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent.

Cui AL, Sun WF, Zhong ZJ, Jin J, Xue ST, Wu S, Li YH, Li ZR. Cui AL, et al. Drug Des Devel Ther. 2020 Sep 15;14:3723-3729. doi: 10.2147/DDDT.S263701. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32982177 Free PMC article.

10

The Low-Alkalinity Polymyxin Derivative, AL-6, Shows High Activity Against Multidrug-Resistant Acinetobacter baumannii Clinical Isolates In Vitro and A. baumannii ATCC 19606 In Vivo: Preliminary Analysis of the Antibacterial Mechanism.

Chen DJ, Cui AL, Chen JR, Yang P, Jin J, Shao L, Li ZR. Chen DJ, et al. Among authors: cui al. Microb Drug Resist. 2021 Jul;27(7):933-941. doi: 10.1089/mdr.2019.0474. Epub 2021 Feb 5. Microb Drug Resist. 2021. PMID: 33544031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters